2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157440
    AChE/Aβ-IN-3
    AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease.
    AChE/Aβ-IN-3
  • HY-157441
    AChE/Aβ-IN-4
    AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC50 values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease.
    AChE/Aβ-IN-4
  • HY-157461
    Glycation-IN-1 3023711-86-3
    Glycation-IN-1 (Compound 3) is an inhibitor of glycosylation reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases.
    Glycation-IN-1
  • HY-157476
    AChE-IN-53 2807436-94-6
    AChE-IN-53 (Compound I-52) is a potent NMDAR inhibitor, which is a compound with favorable behavioral and neuroprotective effects.
    AChE-IN-53
  • HY-157517
    MAO-B-IN-29 122823-57-8
    MAO-B-IN-29 (compound 9a) is a inhibitor against MAO-B activity.
    MAO-B-IN-29
  • HY-157527
    hAChE-IN-7 2978613-03-3
    hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC50=69.8 nM) and hBuChE (IC50=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC50=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research.
    hAChE-IN-7
  • HY-157555
    NLRP3-IN-29 2198483-40-6
    NLRP3-IN-29(Compound 5M) is an inhibitor of NLR family pyrin domain containing 3 (NLRP3). NLRP3-IN-29 has the potential for blood-brain barrier permeability and inflammation inhibition both in vivo and in vitro. NLRP3-IN-29 can be used for research on Alzheimer's disease.
    NLRP3-IN-29
  • HY-157563
    Dopamine D4 receptor ligand 2 219125-63-0
    Dopamine D4 receptor ligand 2 (compound 17) is a potent and selective dopamine D4 ligand with IC50 values of 0.057, >1000, 220, 270 nM for D4, D2, 5-HT1A, α1, respectively.
    Dopamine D4 receptor ligand 2
  • HY-157743
    SCH 60057 203061-35-2
    SCH 60057 (Compound 7) is a neurokinin (NK) receptor inhibitor that can be isolated from Acremonium sp., with IC50 values of 6 μM and 12 μM for NK1 and NK2, respectively.
    SCH 60057
  • HY-157751
    RIPK1-IN-21 3016304-64-3
    RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases.
    RIPK1-IN-21
  • HY-157787
    Ginkgolic acid 2-phosphate 2281761-58-6
    Ginkgolic acid 2-phosphate is a potent sphingosine 1-phosphate agonist. Ginkgolic acid 2-phosphate induces ERK phosphorylation. Ginkgolic acid 2-phosphate interactes with S1P1.
    Ginkgolic acid 2-phosphate
  • HY-157792
    Antidepressant agent 6
    Antidepressant agent 6 (S-3a) is a lead compound with potent and sustained antidepressant effects. Antidepressant agent 6 (S-3a) displays high cognitive safety margin.Antidepressant agent 6 (S-3a) antagonizes M1 receptors and elevates BDNF levels, suggesting its potential as an antidepressant for further exploration.
    Antidepressant agent 6
  • HY-157806
    α-Synuclein inhibitor 12
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases.
    α-Synuclein inhibitor 12
  • HY-15780A
    Brexpiprazole hydrochloride 913612-38-1
    Brexpiprazole (OPC-34712) hydrochloride, an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole hydrochloride is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole hydrochloride also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM).
    Brexpiprazole hydrochloride
  • HY-157931
    Anticancer agent 192
    Anticancer agent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinics and hERG. Anticancer agent 192 is quite stable in human and rat liver microsomes. Anticancer agent 192 can improve the cognitive level and reduce the degree of addiction in rats in the in vivo addiction test.
    Anticancer agent 192
  • HY-157934
    MAO-IN-4 3023217-85-5
    MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC50 values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD).
    MAO-IN-4
  • HY-157935
    17β-HSD10-IN-3 2225109-18-0
    17β-HSD10-IN-3 (compound 23) is a 17β-HSD10 inhibitor with the IC50 of 5.59 μM. 17β-HSD10-IN-3 shows no cell cytotoxicity toward the HEK-293 cell line up to 20 μM.
    17β-HSD10-IN-3
  • HY-157936
    GluN2B-NMDAR antagonist-2
    GluN2B-NMDAR antagonist-2 (compound S-58) is a potent, selective and cross the blood-brain barrier NMDAR-GluN2B antagonist with an IC50 value of 74.01, nM. GluN2B-NMDAR antagonist-2 shows mild cytotoxicity. GluN2B-NMDAR antagonist-2 decreases the cerebral infarction rates and neurologic deficit scores. GluN2B-NMDAR antagonist-2 has the potential for the research of stroke.
    GluN2B-NMDAR antagonist-2
  • HY-15793A
    Trans (2,3)-Dihydrotetrabenazine 171598-74-6
    Trans (2,3)-Dihydrotetrabenazine ((2R,3R,11bR)-rel-Dihydrotetrabenazine), a metabolite of Tetrabenazine, shows remarkable inhibition activity on vesicular monoamine transporter (VMAT2).
    Trans (2,3)-Dihydrotetrabenazine
  • HY-157955
    TAAR1 agonist 1
    TAAR1 agonist 1 (compound 6E) is a potent TAAR1 agonist with a potent TAAR1-Gs/Gq dual-pathway activation property. TAAR1 agonist 1 significantly alleviates MK-801-induced schizophrenia-like cognitive phenotypes.
    TAAR1 agonist 1
Cat. No. Product Name / Synonyms Application Reactivity